Indian market likely to consolidate on Thursday tracking muted global cues, but there will be stock specific action in which global brokerage came out with their reports on business development, or earnings outlook.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

We have collated a list of recommendations from various global brokerage firms according to a Zee Business TV report:

ICICI Lombard: Overweight| Target Rs 1900

See Zee Business Live TV Streaming Below:

Morgan Stanley maintained an overweight rating on ICICI Lombard with a target of Rs 1900 that translates into an upside of over 30 per cent from Rs 1423 recorded on 19 January.

Overall profit was broadly in-line, and loss ratios improved across most product segments. The commentary on business growth & outlook is positive.

Tata Motors: Buy| Target Rs 625

Jefferies maintained buy rating on Tata Motors with a target price of Rs 625 which translates into an upside of nearly 20 per cent from Rs 521 recorded on 19 January.

The global investment bank believes that the company is in the early phase of a multi-year turnaround led by the confluence of improved strategy and cyclical recovery Truck.

PV demand is recovering from the worst slowdown in decades and the company is gaining market share. JLR is improving sequentially which is a positive sign. An early lead in India EVs offers big option value. Tata Motors is Jefferies top auto-pick.

JustDial: Buy| Target Rs 1350

UBS maintained buy rating on JustDial with a target price of Rs 1350 which translates into an upside of over 65 per cent from Rs 815 recorded on 19 January.

The company has taken various steps towards building marketplace e-commerce platforms. It has aggressive plans in B2B, and B2C segments.

Going forward, ramping up the sales network will be a key positive. The global investment bank reduced the FY22 EPS estimate by 12%, factoring in third-wave impact. It also trimmed the FY23-24 EPS estimate by 5-6%.

Apollo Hospitals: Buy| Target Rs 6060

Jefferies maintained a buy rating on Apollo Hospitals and raised the target to Rs 6060 from Rs 5923 earlier which translates into an upside of over 34 per cent from Rs 4515 recorded on 19 January.

The stock corrected by over 10 per cent since 31-December. The price now reflects zero value for digital 24/7 and discounted multiples for hospital and offline pharmacy parts.
 
The global investment bank views the current price as an enhanced entry point.

(Disclaimer: The views/suggestions/advices expressed here in this article is solely by investment experts. Zee Business suggests its readers to consult with their investment advisers before making any financial decision.)